Pardes Biosciences Inc

PRDS | $2.16 1.37% 2.4M

(0.0% 1d) (0.0% 1m) (23.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 133,945,393
https://www.pardesbio.com
Sec Filling | Patents | 3 employees

Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. Pardes is applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.

injection msa antiviral covid

add to watch list Paper trade email alert is off

ImmunoPrecise Antibodies Ltd

IPA | $1.24 0.0% 150K

Professional, Scientific, and T...

(0.0% 1d) (-10.0% 1m) (-59.1% 1y) (0.0% 2d) (-0.8% 3d) (1.6% 7d) (155.05% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 32,630,922
http://www.immunoprecise.com/
Sec Filling | Patents | 2021 employees

(CA) IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company's therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.

covid antibody

add to watch list Paper trade email alert is off

Q BioMed Inc.

QBIO | $0.0002 100.0% 1.1K

Professional, Scientific, and T...

(0.0% 1d) (-99.7% 1m) (-100.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (87.65% volume)
Earnings Calendar:
Market Cap: $ 29,019

Sec Filling | Patents | 6 employees

q biomed inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. the company offers strontium chloride sr89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. it is also developing man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; qbm-001 for rare pediatric non-verbal autism spectrum disorder; and uttroside-b for liver cancer. q biomed inc. has a partnership with mannin research for the development of novel covid-19 therapeutics. the company was formerly known as ismo tech solutions, inc. and changed its name to q biomed inc. in july 2015. q biomed inc. was founded in 2013 and is based in new york, new york.

covid

add to watch list Paper trade email alert is off